{"nctId":"NCT01255423","briefTitle":"Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain","startDateStruct":{"date":"2010-11"},"conditions":["Ankle Sprain"],"count":206,"armGroups":[{"label":"Diclofenac sodium topical gel 1%","type":"EXPERIMENTAL","interventionNames":["Drug: Diclofenac sodium topical gel 1%"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Diclofenac sodium topical gel 1%","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Male or female aged 18 years and over.\n2. Acute sprain of the lateral ankle, Grade I-II, meeting baseline pain intensity level.\n3. Injury within past 12 hours.\n\nExclusion criteria:\n\n1. Pain medication was taken within the 6 hours that precede randomization.\n2. During the past 3 months: Grade I-III sprain of the same ankle.\n3. During the past 6 months: Grade II-III sprain, any other significant injury (such as fracture or torn ligament), or surgery (except for skin or nails) of the same ankle or foot.\n4. Pain or instability in the same ankle attributable to previous ankle sprain or any other trauma.\n5. Ankle sprain attributable to a known disease affecting the ligaments, such as ligament hyperlaxity due to connective tissue disease (e.g., Marfan's syndrome, Down's syndrome, Ehlers-Danlos syndrome).\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pain on Movement","description":"Pain on movement at 72 hours assessed on a 100 mm visual analog scale with anchors at 0= \"No pain\" and 100= \"Extreme pain\"","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.4","spread":"25.2"},{"groupId":"OG001","value":"38.8","spread":"24.1"}]}]}]},{"type":"SECONDARY","title":"Pain on Movement","description":"Pain on movement at 24 hours and 7 days assessed on a 100 mm visual analog scale with anchors at 0= \"No pain\" and 100= \"Extreme pain\"","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","spread":"22.5"},{"groupId":"OG001","value":"53.1","spread":"22.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":"23.1"},{"groupId":"OG001","value":"22","spread":"23.5"}]}]}]},{"type":"SECONDARY","title":"Onset of Pain Relief","description":"Onset of perceptible pain relief","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Tenderness","description":"Tenderness at 24 and 72 hours and 7 days. Change from baseline. Tenderness was measured by a calibrated algometer in order to quantify the pressure pain threshold, a measure of tenderness.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"8.2"},{"groupId":"OG001","value":"1.3","spread":"7.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":"11.9"},{"groupId":"OG001","value":"5.5","spread":"11.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":"13.3"},{"groupId":"OG001","value":"11.9","spread":"10.6"}]}]}]},{"type":"SECONDARY","title":"Ankle Joint Function","description":"Ankle joint function score (Karlsson Scoring scale which ranges from 0 \"worst possible score\" to 90 \"best possible score\")at 24 and 72 hours and 7 days.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":"18.7"},{"groupId":"OG001","value":"30.7","spread":"17.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":"19.3"},{"groupId":"OG001","value":"46.1","spread":"19.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":"20.0"},{"groupId":"OG001","value":"66.4","spread":"21.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":104},"commonTop":["Nervous Sytem disorders","Musculoskeletal and connective tissue disorder","Skin and subcutaneous tissue disorders","Infection and infestations","General disorders and administration site conditions"]}}}